VNDA — Vanda Pharmaceuticals Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1347178 ·
Last close
$5.05
Market Cap
$305.34M
52W High
$9.94
52W Low
$4.27
ADV30
787,183
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 50,529,000 | 46,969,000 | -63,809,000 | -62,513,000 | 412,467,000 | 55,882,000 | 192,282,000 |
| Mar 2026 | 51,718,000 | 48,559,000 | -50,224,000 | -48,567,000 | 433,525,000 | 54,034,000 | 152,760,000 |
| Dec 2025 | 57,216,000 | 53,383,000 | -40,353,000 | -141,187,000 | 488,948,000 | 84,851,000 | 161,762,000 |
| Sep 2025 | 56,258,000 | 53,304,000 | -31,284,000 | -22,586,000 | 601,140,000 | 70,022,000 | 135,141,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-126,513,000
Investing CF
$71,192,000
Financing CF
$-2,358,000
CapEx
$-10,783,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.05
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-505,846,000
Inventory
$1,678,000
Receivables
$59,692,000
ST Investments
$114,147,000
EBIT TTM
$-185,670,000
Pretax Income TTM
$-177,200,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$215,720,992
EBITDA
$-177,047,008
Free Cash Flow
$-86,717,752
Enterprise Value
$160,558,080
Total Cash
$170,028,992
Total Debt
$22,832,000
Shares Out
60,462,687
Trailing EPS
$-4.64
Book Value
$4.67
ROE
-77.8%
ROA
-22.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 216,105,000 | -151,168,000 | -220,474,000 | 488,948,000 | 161,762,000 | 327,186,000 | -109,442,000 |
| Dec 2024 | 198,772,000 | -40,660,000 | -18,900,000 | 656,204,000 | 117,658,000 | 538,546,000 | -15,757,000 |
| Dec 2023 | 192,640,000 | -13,952,000 | 2,509,000 | 648,440,000 | 103,530,000 | 544,910,000 | 12,801,000 |
| Dec 2022 | 254,382,000 | 6,329,000 | 6,275,000 | 634,247,000 | 107,049,000 | 527,198,000 | 31,984,000 |
TTM Snapshot
Revenues TTM
$210,264,000
NetIncome TTM
$108,991,000
OpCashFlow TTM
$0
Assets (Latest)
$533,456,000
Forward EPS
$0.20
Max Pain — expiry 2026-12-18
max pain strike: $5.00 · spot: $5.10 · call oi: 5,347 · put oi: 1,087
Expected Move to 2026-12-18:
±$2.05
(40.20%) —
implied range
$3.05 –
$7.15
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EVMN | Evommune, Inc. | $308.12M | $8.49 | — |
| ABEO | ABEONA THERAPEUTICS INC. | $308.79M | $5.40 | — |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $316.69M | $3.95 | — |
| UPB | Upstream Bio, Inc. | $293.57M | $5.36 | — |
| CYDY | CytoDyn Inc. | $317.85M | $0.23 | — |
News headlines (Yahoo Finance, 1h cache)
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
2026-09-02 20:30 · Yahoo
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
2026-08-22 19:16 · Yahoo
Vanda (VNDA) Q2 2026 Earnings Call Transcript
2026-08-12 23:13 · Yahoo
Vanda Pharmaceuticals Q2 Earnings Call Highlights
2026-08-06 07:03 · Yahoo
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
2026-08-05 20:01 · Yahoo
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
2026-07-16 20:30 · Yahoo
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
2026-07-10 20:30 · Yahoo
VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy
2026-07-08 00:22 · Yahoo
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
2026-07-07 20:30 · Yahoo
Here’s Why H.C. Wainwright Remains a Buy on Vanda Pharmaceuticals (VNDA)
2026-07-03 13:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.